Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2026-01-06 @ 10:37 PM
Study NCT ID:
NCT02086604
Status:
COMPLETED
Last Update Posted:
2022-02-17
First Post:
2014-03-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sponsor:
Washington University School of Medicine
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-09-18
Start Date Type:
ACTUAL
Primary Completion Date:
2017-06-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-01-12
Completion Date Type:
ACTUAL
First Submit Date:
2014-03-11
First Submit QC Date:
None
Study First Post Date:
2014-03-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-16
Last Update Post Date:
2022-02-17
Last Update Post Date Type:
ACTUAL